Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.

Sofroniadou S, Goldsmith D.

Drug Saf. 2011 Feb 1;34(2):97-115. doi: 10.2165/11585040-000000000-00000.

PMID:
21247219
[PubMed - indexed for MEDLINE]
2.

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Teachey DT, Grupp SA, Brown VI.

Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. Review.

PMID:
19344392
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

PMID:
22845486
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.

Khokhar NZ, Altman JK, Platanias LC.

Curr Opin Oncol. 2011 Nov;23(6):578-86. doi: 10.1097/CCO.0b013e32834b892d. Review.

PMID:
21892085
[PubMed - indexed for MEDLINE]
5.

Adverse events associated with mTOR inhibitors.

Pallet N, Legendre C.

Expert Opin Drug Saf. 2013 Mar;12(2):177-86. doi: 10.1517/14740338.2013.752814. Epub 2012 Dec 20. Review.

PMID:
23252795
[PubMed - indexed for MEDLINE]
6.

Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.

Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A.

Clin Dev Immunol. 2013;2013:403280. doi: 10.1155/2013/403280. Epub 2013 Sep 19. Review.

PMID:
24151517
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.

Xu J, Tian D.

Curr Med Res Opin. 2014 Jan;30(1):67-74. doi: 10.1185/03007995.2013.844116. Epub 2013 Oct 4. Review.

PMID:
24028709
[PubMed - indexed for MEDLINE]
8.

mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

Grzybowska-Izydorczyk O, Smolewski P.

Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Review.

PMID:
22416776
[PubMed - indexed for MEDLINE]
9.

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

Sankhala K, Giles FJ.

Expert Rev Hematol. 2009 Aug;2(4):399-414. doi: 10.1586/ehm.09.31.

PMID:
21082945
[PubMed - indexed for MEDLINE]
10.

Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use.

Touzot M, Soulillou JP, Dantal J.

Curr Opin Organ Transplant. 2012 Dec;17(6):626-33. doi: 10.1097/MOT.0b013e32835a4be2. Review.

PMID:
23080066
[PubMed - indexed for MEDLINE]
11.

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.

Kahan B.

Expert Opin Drug Saf. 2011 Sep;10(5):727-49. doi: 10.1517/14740338.2011.579898. Epub 2011 May 11. Review.

PMID:
21557712
[PubMed - indexed for MEDLINE]
12.

[Use of mTOR-inhibitors in solid tumors].

Seidel C, Grünwald V.

Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Review. German.

PMID:
21528529
[PubMed - indexed for MEDLINE]
13.

Rapamycin passes the torch: a new generation of mTOR inhibitors.

Benjamin D, Colombi M, Moroni C, Hall MN.

Nat Rev Drug Discov. 2011 Oct 31;10(11):868-80. doi: 10.1038/nrd3531. Review.

PMID:
22037041
[PubMed - indexed for MEDLINE]
14.

Mammalian target of rapamycin as a target in hematological malignancies.

Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS.

Target Oncol. 2011 Mar;6(1):53-61. doi: 10.1007/s11523-011-0175-8. Epub 2011 Apr 17. Review.

PMID:
21499765
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.

Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.

PMID:
21932373
[PubMed - indexed for MEDLINE]
Free Article
16.

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.

Transplant Proc. 2010 Oct;42(8):3050-2. doi: 10.1016/j.transproceed.2010.07.083.

PMID:
20970607
[PubMed - indexed for MEDLINE]
17.

Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.

Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD.

Ann Oncol. 2013 Aug;24(8):2092-7. doi: 10.1093/annonc/mdt155. Epub 2013 May 8.

PMID:
23658373
[PubMed - indexed for MEDLINE]
Free Article
18.

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.

Coiffier B, Ribrag V.

Leuk Lymphoma. 2009 Dec;50(12):1916-30. doi: 10.3109/10428190903207548. Review.

PMID:
19757306
[PubMed - indexed for MEDLINE]
19.

mTOR inhibition and erythropoiesis: microcytosis or anaemia?

Diekmann F, Rovira J, Diaz-Ricart M, Arellano EM, Vodenik B, Jou JM, Vives-Corrons JL, Escolar G, Campistol JM.

Nephrol Dial Transplant. 2012 Feb;27(2):537-41. doi: 10.1093/ndt/gfr318. Epub 2011 Jul 22.

PMID:
21785038
[PubMed - indexed for MEDLINE]
Free Article
20.

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.

Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H.

Oncologist. 2012;17(1):135-44. doi: 10.1634/theoncologist.2011-0111. Epub 2011 Dec 29. Review.

PMID:
22207567
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk